Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma

摘要: Topoisomerase (TOP) gene copy number changes may predict response to treatment with TOP-targeting drugs in cancer treatment. This was first described patients breast and is currently being investigated other malignant diseases. induce TOP at relapse, possible implications for relapse therapy efficacy. alterations lymphoma are poorly investigated. In this study, TOP1 TOP2A were de novo diffuse large B-cell (DLBCL) (n = 33) relapsed DLBCL treated chemotherapy regimens including TOP2-targeting (n = 16). No or found. Polysomy of chromosomes 20 17 seen 3 25 (12%) 2 32 (6%) DLBCL. Among patients, chromosome polysomy more frequently observed 5 13 (38%) 4 16 (25%) harboring polysomy, respectively; however, these differences only tended be significant ( p  = 0.09  = 0.09, respectively). The results suggest that very infrequent not likely induced by drugs. Increased polyploidy among reflect genetic compensation the tumor cells after TOP2 inhibition, but due increased instability often progressed cancers. Therefore, it unlikely can used as predictive markers